Physician profile
D'Amico Johnson
NPI 1952805269
$353.67
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $245 · 2022: $108.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $59.49 | 2021-2022 | |
| Novo Nordisk INC | $52.91 | 2021-2022 | |
| Abbvie INC. | $43.08 | 2021-2022 | |
| Amarin Pharma, INC. | $23.17 | 2021 | |
| Bardy Diagnostics, INC. | $22.00 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $20.98 | 2022 | |
| Pfizer INC. | $20.54 | 2021 | |
| Amgen INC. | $16.93 | 2022 | |
| Lilly USA, LLC | $16.65 | 2022 | |
| Clarus Therapeutics INC. | $14.43 | 2021 | |
| Merck Sharp & Dohme LLC | $13.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $13.20 | 2021 | |
| Medtronic, INC. | $12.63 | 2021 | |
| Eisai INC. | $12.34 | 2021 | |
| Phadia US INC. | $11.47 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw D'Amico Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.